Opinion|Videos|July 29, 2024
Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
A panel of experts discuss navigating 2L treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your perceptions on efficacy and safety data on PROTAC
ASCO 2024 #TPS1131 TACTIVE-K: Phase 1b/2 study of vepdegestrant plus CDK4i PF-07220060
- What are your perceptions on efficacy and safety data on SERM:
- Lasoxifene:
ASCO 2024 #TPS1127 : Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib
- Lasoxifene:
- How do these options compare? Why might you choose one of these options vs fulvestrant?
Advertisement
Related to this article
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.
Obesity may increase breast cancer risk partly by removing a natural defense.
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5